Article
Oncology
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo' Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta
Summary: The study validates the effectiveness of the Molecular International Prognostic Scoring System (IPSS-M) in predicting clinical outcomes of patients with myelodysplastic syndromes (MDS). IPSS-M improves the prognostic discrimination of the Revised International Prognostic Scoring System (IPSS-R) and enhances the accuracy of selecting candidates for hematopoietic stem cell transplantation (HSCT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Luis E. E. Aguirre, Najla Al Ali, David A. A. Sallman, Somedeb Ball, Akriti G. G. Jain, Onyee Chan, Sara M. M. Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. E. Lancet, Eric Padron, Rami S. S. Komrokji
Summary: The Molecular International Prognostic Scoring System (IPSS-M) is a new risk stratification model for myelodysplastic syndromes (MDS) that incorporates mutational data to improve prognostic accuracy. In a large cohort of MDS patients, the IPSS-M was validated and found to be accurate in predicting overall survival (OS), leukemia-free survival (LFS), and leukemic transformation. The model also showed validity in therapy-related and hypoplastic MDS. The use of this tool can lead to more accurate prognostic assessment and optimized therapeutic decision-making in MDS.
Letter
Hematology
Chantana Polprasert, Pimjai Niparuck, Thanawat Rattanathammethee, Sirorat Kobbuaklee, Theerin Lanamtieng, Ponlapat Rojnuckarin
Summary: The study examines the performance of M-IPSS and R-IPSS in Thai patients with MDS. The results show that R-IPSS score can be used for risk stratification in most Thai patients. However, there were discrepancies in re-staging between the two methods in 8% of cases, which may affect treatment decisions.
Article
Oncology
Wan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, Feng-Ming Tien, Min-Yen Lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Yi-Tsung Yang, Jui-Che Chen, Jih-Luh Tang, Hsun- Sun, Yi-Kuang Chuang, Liang-In Lin, Wen-Chien Chou, Chien-Chin Lin, Hsin-An Hou, Hwei-Fang Tien
Summary: This study validated the use of the IPSS-M in patients with MDS and compared its prognostic power to the IPSS and IPSS-R. The IPSS-M showed better predictive ability and could help in optimizing therapeutic decision-making for MDS patients. Additional genetic analysis, including KMT2A-PTD, was recommended for accurate IPSS-M categorization of specific patient subgroups.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Youshan Zhao, Juan Guo, Sida Zhao, Roujia Wang, Dong Wu, Chunkang Chang
Summary: This study found that bone marrow fibrosis (BMF) is an independent significant prognostic factor for myelodysplastic syndromes (MDS), and adding it to the IPSS-R can improve its predictive capability.
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Yujiao Jia, Chengwen Li, Huijun Wang, Qingyan Gao, Wenyu Cai, Jingye Gong, Songyang Zhao, Fuhui Li, Robert Peter Gale, Zhijian Xiao
Summary: This study compared the survival prediction accuracy of two risk models, IPSS-R and IPSS-M, in 852 patients with myelodysplastic syndromes. It found that IPSS-M showed higher accuracy in predicting survival in patients aged 60 and above, possibly due to a higher frequency of mutations related to survival in this age group.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Cong Shi, Shengping Gong, An Wu, Shujun Yang, Duobing Zou, Yi Zhang, Ningning Wu, Chao Ma, Songqiu Shi, Ying Chen, Ying Wu, Xiaojiao Zheng, Zhenya Huang, Jianghua Ding, Guifang Ouyang, Qitian Mu
Summary: The study found that low ApoA1 levels in MDS patients are associated with shorter overall survival and a higher frequency of TP53 mutation. Age, gender, hemoglobin levels, bone marrow blast percentage, IPSS-R scores, and karyotype are significantly associated with overall survival, while low ApoA1 levels do not affect leukemia-free survival.
Article
Biochemistry & Molecular Biology
Hussein Awada, Carmelo Gurnari, Arda Durmaz, Hassan Awada, Simona Pagliuca, Valeria Visconte
Summary: Myelodysplastic syndromes (MDS) have variable clinical manifestations and prognoses. Prognostic systems have been developed to categorize MDS patients into different risk groups based on clinical factors and cytogenetic abnormalities. Incorporating molecular features into these systems may enhance their prognostic power. Machine learning algorithms can help develop precise prognostication models by integrating complex genomic interactions. This review highlights current prognostic models used in MDS and the latest achievements in machine learning-based research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Yudi Zhang, Junying Wu, Zefeng Xu, Tiejun Qin, Shiqiang Qu, Lijuan Pan, Huijun Wang, Qi Sun, Chengwen Li, Yujiao Jia, Wenyu Cai, Xin Yan, Jingye Gong, Qingyan Gao, Bing Li, Robert Peter Gale, Zhijian Xiao
Summary: The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs further investigation. Based on our analysis of data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria, we found that the ICC criteria of MDS-SF3B1 identifies a more homogeneous disease entity than the WHO 2016 criteria of myelodysplastic syndromes with ring sideroblasts (MDS-RS). Additionally, our analysis revealed that MDS, not otherwise specified with single lineage dysplasia (MDS, NOS-SLD) patients have a better prognosis than MDS, NOS with multilineage dysplasia (MDS, NOS-MLD) patients, and that MDS patients with mutated TP53 and MDS/acute myeloid leukemia with mutated TP53 exhibit the shortest survival time. These findings support the use of the ICC for more accurate diagnosis and risk stratification of MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Guillermo Montalban-Bravo, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Farhad Ravandi, Kelly Chien, Naveen Pemmaraju, Danielle Hammond, Xiao Qin Dong, Xuelin Huang, Heather Schneider, Rosmy John, Rashmi Kanagal-Shamana, Sanam Loghavi, Hagop Kantarjian, Guillermo Garcia-Manero
Summary: Lower doses of CPX-351 show promising safety and activity in HR-MDS or CMML patients who have failed HMAs.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medical Laboratory Technology
Bifa Lai, Yongyu Chen, Minjun Li, Guohua Ye, Huashan Luo, Yonghong Zhong, Xuemin Guo
Summary: Myelodysplastic syndromes (MDS) are a class of myeloid neoplasms characterized by inefficient maturation and differentiation of hematopoietic cells. Diagnosis of MDS is challenging due to its complexity, but establishing an FCM scoring system (FCSS) has been found to be a convenient and affordable approach for diagnosis and prognostic stratification.
CLINICAL LABORATORY
(2022)
Article
Hematology
Yu-Hung Wang, Hsin-An Hou, Chien-Chin Lin, Yuan-Yeh Kuo, Chi-Yuan Yao, Chia-Lang Hsu, Mei-Hsuan Tseng, Cheng-Hong Tsai, Yen-Ling Peng, Chein-Jun Kao, Wen-Chien Chou, Hwei-Fang Tien
Summary: This study revealed the association between immune cell ratios in the bone marrow of MDS patients and prognosis, with the ICSS scoring system able to stratify patients into high, intermediate, and low-risk groups and independently predict prognosis.
Article
Oncology
Tobias Silzle, Sabine Blum, Annika Kasprzak, Kathrin Nachtkamp, Martina Rudelius, Barbara Hildebrandt, Katharina S. Goetze, Norbert Gattermann, Michael Lauseker, Ulrich Germing
Summary: The absolute monocyte count (AMC) at the time of diagnosis in myelodysplastic syndromes (MDS) has a prognostic impact independent of the revised international prognostic scoring system (IPSS-R). Patients with a low AMC (<0.2 x 10(9)/L) have a higher risk of transformation to acute myeloid leukemia. Considering the AMC might help identify MDS patients who could benefit from more intense treatment strategies.
Review
Hematology
Zhuoer Xie, Evan C. Chen, Maximilian Stahl, Amer M. Zeidan
Summary: Accurate risk prognostication is crucial for managing myelodysplastic syndromes (MDS) due to their diverse clinical outcomes. Advances in MDS genomics have provided unprecedented insight into MDS pathobiology, leading to the development of molecular prognostic models. These models, such as the IPSS-M, improve risk prediction but also introduce complexity. This review discusses early MDS prognostic models, recent advancements in MDS genomics, and the challenges and opportunities at the molecular frontier.
Review
Oncology
Virginia O. Volpe, Guillermo Garcia-Manero, Rami S. Komrokji
Summary: Myelodysplastic syndromes (MDS) is a group of heterogeneous clonal hematopoietic stem cell disorders with an increasing incidence rate with age. Risk stratification, prognosis, survival, and AML transformation in MDS depend largely on the revised International Prognostic Scoring System and molecular genetic testing. Treatment varies based on disease severity, with low-risk MDS aimed at alleviating anemia symptoms and high-risk MDS requiring prompt initiation of hypomethylating agents. Allogeneic stem cell transplant may be the only potential cure for high-risk MDS.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
